NPC patients with undetectable level of plasma EBV DNA post-RT have a lower risk of recurrence, and tend to have an increase in frequency of chemoattractant (CCR1/4/5)-expressing CD8 T cells in blood during RT. The frequency of chemoattractant-expressing CD8 T cells is positively correlated with the frequency of OX40-expressing CD8 T cells, and negatively with those of PD1-expressing CD8 T cells. These translational data upon validation may suggest that on-treatment increase in frequency of chemoattractant-expressing CD8 T cells represents a blood-based immune marker for NPC patients with lower risk of recurrence.

**CONCLUSION**

Low risk NPC patients demonstrate in blood:
- lowered frequency of PD1+ CD8 T cells at week 4 during RT and post RT compared to high risk patients
- increase in frequency of OX40+ CD8 T cells at post RT compared to pre-treatment

Low risk NPC patients demonstrate in blood:
- lowered frequency of CXCR3+ CD8 T cells at week 4 during RT compared to high risk patients
- increase in frequency of CCR1/4/5+ CD8 T cells during and post-RT compared to pre-treatment

Frequency of CCR1/4/5+ CD8 T cells correlates positively with frequency of OX40+ CD8 T cells, yet correlates negatively with frequency of PD1+ CD8 T cells

**REFERENCES**